Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rislenemdaz (CERC-301) (CERC-301) is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 147.00 | |
5 mg | In stock | $ 447.00 | |
10 mg | In stock | $ 659.00 | |
25 mg | In stock | $ 987.00 | |
50 mg | In stock | $ 1,390.00 | |
100 mg | In stock | $ 1,880.00 | |
500 mg | In stock | $ 3,780.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 352.00 |
Description | Rislenemdaz (CERC-301) (CERC-301) is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B). |
Targets&IC50 | GluN2B:3.6 nM, NMDA receptors, type 1A/2B:< 50 μM, GluN2B:8.1 nM (ki), NMDA NR2B:< 50 μM, NMDA receptors, type 2B:0.0036 μM |
In vitro | rislemdaz (CERC-301) inhibited calcium influx in agonist stimulated NMDA-GluN1a/GluN2B L(tk-) cells. rislemdaz (CERC-301) had an IC50 of 3.6 nM. rislemdaz is highly selective for GluN2B receptors. rislemdaz showed minimal activity against sigma-type receptors at a concentration of 10 uM[1]. |
Synonyms | CERC-301, MK-0657 |
Molecular Weight | 358.41 |
Formula | C19H23FN4O2 |
CAS No. | 808732-98-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (251.1 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Rislenemdaz 808732-98-1 Membrane transporter/Ion channel Neuroscience iGluR CERC301 MK 0657 CERC-301 MK-0657 CERC 301 MK0657 inhibitor inhibit